Swedish biotech Gesynta Pharma has secured SEK 304 million ($29 million) in Series B funding to advance its novel non-hormonal endometriosis treatment. The round was led by Innovestor Life Science, with participation from existing and new investors including Hadean Ventures, Industrifonden, Linc, Foreground Capital, Catalyze Capital, Stephen Industries, and Amboy Street Ventures. The funding will support a Phase II clinical trial of…
Celmatix announced a new drug development program targeting endometriosis through a novel Jun-N-terminal kinase (JNK) inhibitor. The therapeutic candidate, developed using Baylor College of Medicine‘s DNA-Encoded Chemistry Technology platform, aims to address pain and inflammation associated with endometriosis. The program targets a significant medical need, as endometriosis affects over 10% of girls and women aged 15-45 worldwide. In the US, the condition…
Freya Biosciences, a biotech company focused on women’s health, has secured a $10.4 million strategic investment from the Bill & Melinda Gates Foundation, along with $1.4 million additional financing from EIFO (Export and Investment Fund of Denmark). The funding extends the company’s Series A to approximately $50 million. The investment will support the expansion of Freya’s DYSCOVERTM platform to develop microbial immunotherapies…
Parallel Fluidics, a company developing on-demand microfluidic manufacturing solutions with applications in IVF and other life science fields, has secured $7 million in seed funding. The round was led by J2 Ventures with participation from 8VC and Praxis. The company’s technology is already making waves in the fertility sector. Overture Life, a startup focused on simplifying IVF procedures, is utilizing Parallel Fluidics’…
Rallybio has received approval to begin testing a preventive treatment for a rare but serious pregnancy complication that affects mothers and their unborn babies. The condition, known as fetal and neonatal alloimmune thrombocytopenia (FNAIT), occurs when a pregnant woman’s immune system attacks her baby’s platelets, potentially causing dangerous bleeding in the fetus or newborn. The company will begin Phase 2 clinical trials…
Cartherics, an Australian biotech company developing immune cell therapies, has announced the successful completion of an oversubscribed private financing round, raising over AU$15 million. This funding will primarily support the clinical trial of CTH-401, the company’s lead cell therapy for ovarian cancer, and expand its pipeline to include other diseases. Based in Melbourne, Cartherics focuses on developing cell-based immunotherapies for cancer treatment.…
Helaina, a biotechnology company focused on human equivalent bioactive proteins, has announced a $45 million Series B funding round bringing the company’s total equity funding to $83 million. Avidity Partners led the round, with participation from Spark Capital, Ingeborg Investments, Tom Williams of Heron Rock, Barrel Ventures, Siam Capital, Relish Works, CF Private Equity, and Primary Venture Partners, among others. The funding…
U-Ploid, a venture-backed biotech company, has introduced its new platform designed to enhance the quality of older egg cells, a critical factor in increasing the success rates of in vitro fertilization (IVF) for women experiencing age-related infertility. The company’s technology aims to repair decades of accumulated damage in eggs, thereby improving their viability during IVF treatments. Age-related fertility decline affects millions worldwide,…
